Please join the Elicio Therapeutics management team for a virtual key opinion leader (KOL) event to discuss the significant unmet need and current treatment landscape for mutant-KRAS (mKRAS) pancreatic ductal adenocarcinoma (PDAC), one of the most lethal and underserved solid tumors.

The event will feature insights from leading experts:

• Darrell Irvine, Ph.D. – Department of Immunology & Microbiology, The Scripps Research Institute, Howard Hughes Medical Institute
• Eileen O’Reilly, M.D. – FASCO Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center

The event will provide an overview of Elicio’s proprietary lymph node-targeting amphiphile (AMP) technology, which powers Elicio’s development of next-generation vaccines, immunomodulators, and adjuvants designed to generate potent and durable responses. The discussion will also focus on Elicio’s lead product candidate, ELI-002, an AMP-powered therapeutic vaccine designed to overcome immune evasion. ELI-002 is currently being evaluated in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-mutated PDAC, and an event-driven disease-free survival interim analysis of the study is anticipated in Q3 2025.

A live question and answer session will follow the formal presentations.